26 to 35 of 54 results

Sanofi to top Pfizer as number one for global pharma sales


French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

Proteon Thera gets new funding of $15 million, ahead of Novartis acquisition option


US privately-held biopharmaceutical firm Proteon Therapeutics, the subject of a takeover option by Swiss…

BiotechnologyFinancialMergers & AcquisitionsNovartisPharmaceuticalProteon TherapeuticsResearch

Novartis finally gets Alcon; vildagliptin now available for elderly type 2 diabetics in UK


In what looks to be the last hurdle for Swiss drug major Novartis (NOVN: VX) to take full control of…

AlconDiabetesMergers & AcquisitionsNovartisOphthalmicsPharmaceuticalRegulationvildagliptin

Meda buys global rights to Novartis’ Elidel for $420 million


Swiss drug major Novartis(NOVN: VX) has signed an agreement to sell to Swedish drugmaker Meda AB (MEDA:…

DermatologicalsElidelLicensingMedaMergers & AcquisitionsNovartisPharmaceuticalValeant Pharmaceuticals

Novartis completes buy of 85% stake in Chinese vaccine maker Tianyuan


Swiss drug major Novartis (NOVN: VX) said this morning that it has now completed the transaction to acquire…

Asia-PacificMergers & AcquisitionsNovartisPharmaceuticalTianyuanVaccines

Novartis to acquire companion diagnostics maker Genoptix for around $470: Sanofi extends Genzyme offer


Swiss drug major Novartis (NOVN: VX) has entered into a definitive agreement to buy USA-based Genoptix…

GenoptixGenzymeMergers & AcquisitionsNovartisPharmaceuticalSanofi-Aventis

Novartis finally reaches agreement with Alcon’s minority shareholders for full control


Ending a long struggle to gain 100% control of eye care specialist Alcon (NYSE: ACL), Swiss drug major…

AlconMergers & AcquisitionsNovartisOpthalmicsPharmaceutical

Novartis to buy Sanofi-Aventis’ 49% stake in Chiron Behring JV for $22.4 million


Aiming to resolve a long-running dispute relating to the rabies vaccine Rabipur, French drug major Sanofi-Aventis’…

Asia-PacificChiron BehringMergers & AcquisitionsNovartisPharmaceuticalRabipurSanofi-AventisVaccines

Aires Pharma signs option deal with Novartis based on Aironite worth up to $250 million; raises $20 million


Privately-held, US clinical stage pharmaceutical company Aires Pharmaceuticals had a successful fundraising…

Aires PharmaceuticalsAironiteFinancialLicensingMergers & AcquisitionsNovartisPharmaceuticalRespiratory and Pulmonary

26 to 35 of 54 results



Back to top